Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended): An essentially pure composition of one or more members of the FRIL family of progenitor cell preservation factors wherein each FRIL family member binds to a normally glycosylated FLT3 receptor, wherein each FRIL family member preserves progenitor cells, and wherein a FRIL family member isolated from *Dolichos lab lab* comprises the amino acid sequence TNNVLQXT (SEQ ID NO: 24).

Claim 2. (Original): The composition of claim 1, wherein the FRIL family member is from a legume.

Claim 3. (Original): The composition of claim 2, wherein the legume is *Phaseolus vulgaris.*

Claim 4. (Original): The composition of claim 2, wherein the legume is *Dolichos lab lab.*

Claim 5. (Original): The composition of claim 2, wherein the legume is *Sphenostylis stenocarpa.*

Claims 6-8. (Cancelled)

Claim 9. (Currently Amended): A pharmaceutical formulation comprising ~~the composition of claim 1~~ an essentially pure composition of one or more members of the FRIL family of progenitor cell preservation factors wherein each FRIL family member binds to a normally glycosylated FLT3 receptor, and wherein each FRIL family member preserves progenitor cells; and a pharmaceutically acceptable carrier.

Claim 10. (Original): The formulation of claim 9, wherein administration of an effective amount of the formulation to a patient prior to treatment of the patient with a therapeutic treatment having a hematopoietic progenitor-cell depleting activity alleviates or reduces the hematopoietic progenitor cell-depleting activity of the therapeutic treatment in the patient.

Claim 11. (Original): The formulation of claim 10, wherein the patient is human.

Claim 12. (Original): The formulation of claim 11, wherein the patient has cancer.

Claim 13. (Original): The formulation of claim 12, wherein the therapeutic treatment is selected from the group consisting of a radiotherapeutic, a chemotherapeutic, or a combination of a radiotherapeutic and a chemotherapeutic.

Claim 14. (Original): The composition of claim 13, wherein the chemotherapeutic is selected from the group consisting of cytarabine, doxorubicin, and 5-fluorouracil.

Claims 15-60. (Cancelled)

Claim 61. (Currently Amended): An essentially pure composition of a FRIL family member, the FRIL family member being identified by contacting a candidate compound with a glycosylated extracellular domain of an FLT3 receptor, wherein the glycosylation pattern of the extracellular domain of the FLT3 receptor is the same as the glycosylation pattern of an extracellular domain of a normally glycosylated FLT3 receptor, and identifying a candidate compound that binds the glycosylated extracellular domain of the FLT3 receptor as the FRIL family member ~~identified by the method of claim 57~~.

Claim 62. (New): The composition of claim 9, wherein the FRIL family member is from a legume.

Claim 63. (New): The composition of claim 10, wherein the legume is *Phaseolus vulgaris*.

Claim 64. (New): The composition of claim 10, wherein the legume is *Dolichos lab lab*.

Claim 65. (New): The composition of claim 64, wherein FRIL family member isolated from *Dolichos lab lab* comprises the amino acid sequence TNNVLQXT (SEQ ID NO: 24).

Claim 66. (New): The composition of claim 10, wherein the legume is *Sphenostylis stenocarpa.*

Claim 67. (New): The composition of claim 61, wherein the FRIL family member is from a legume.

Claim 68. (New): The composition of claim 62, wherein the legume is *Phaseolus vulgaris*.

Claim 69. (New): The composition of claim 62, wherein the legume is *Dolichos lab lab*.

Claim 70. (New): The composition of claim 69, wherein FRIL family member isolated from *Dolichos lab lab* comprises the amino acid sequence TNNVLQXT (SEQ ID NO: 24).

Claim 71. (New): The composition of claim 62, wherein the legume is *Sphenostylis stenocarpa.*

Claim 72. (New): A pharmaceutical formulation comprising:

(a) an essentially pure composition of one or more members of the FRIL family of progenitor cell preservation factors wherein each FRIL family member binds to a normally glycosylated FLT3 receptor and wherein each FRIL family member preserves progenitor cells;

(b) a chemotherapeutic selected from the group consisting of cytarabine, doxorubicin, and 5-fluorouracil; and

(c) a pharmaceutically acceptable carrier.